News
Clinical Trials Arena on MSN14h
Apnimed doses first subject in trial for sleep apnoea with central componentUS-based Apnimed has dosed the first subject in the multi-centre Phase IIA RESTEADY trial of SASS-001, an oral drug combo for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback